Identification of Compounds with Nanomolar Binding Affinity for Checkpoint Kinase-1 Using Knowledge-Based Virtual Screening

Journal of Medicinal Chemistry

Volumn 47, Issue 8, 2004, Pages 1962-1968

  Lyne, Paul D ^a   Kenny, Peter W ^a   Cosgrove, David A ^a   Deng, Chun ^a   Zabludoff, Sonya ^a   Wendoloski, John J ^a   Ashwell, Susan ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; CHECKPOINT KINASE 1; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; SB 218078; STAUROSPORINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DATA BASE; DRUG BINDING SITE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; IC 50; PHARMACOPHORE; VIRTUAL REALITY; X RAY CRYSTALLOGRAPHY;

AMINO ACID MOTIFS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; ENZYME INHIBITORS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1842450527     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030504i     Document Type: Article

References (40)

1. Hanahan, D.; Weinberg, R. A. The Hallmarks of Cancer. Cell 2000, 100, 57-70.
2. Zhou, B.-B. S.; Elledge, S. J. The DNA Damage Response: Putting Checkpoints in Perspective. Nature 2000, 408, 433-439.
3. Sanchez, Y.; Wong, C.; Thoma, R. S.; Richman, R.; Wu, Z.; et al. Conservation of the DNA Checkpoint Pathway in Mammals: Linkage of DNA Damage to Cdk Regulation Through Cdc25. Science 1997, 277, 1497-1501.
4. Graves, P. R.; Yu, L.; Schwarz, J. K.; Gales, J.; Sausville, E. A.; et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the abticancer agent UCN-01. J. Biol. Chem. 2000, 275, 5600-5605.
5. Jackson, J. R.; Gilmartin, A.; Imburgia, C.; Winkler, J. D.; Marshall, L. A.; et al. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res. 2000, 60, 566-572.
6. Bajorath, J. Integration of virtual and high throuput screening. Nat. Rev. Drug Discovery 2002, 1, 882-894.
7. Lyne, P. D. Structure-based virtual screening: an overview. Drug Discovery Today 2002, 7, 1047-1055.
8. Schneider, G.; Bohm, H. J. Virtual screening and fast automated docking methods. Drug Discovery Today 2002, 7, 64-70.
9. Abagyan, R.; Totrov, M. High-throughput docking for lead generation. Curr. Opin. Chem. Biol. 2001, 5, 375-382.
10. Bissantz, C.; Folkers, G.; Rognan, D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J. Med. Chem. 2000, 43, 4759-4767.
11. Stahl, M.; Rarey, M. Detailed analysis of scoring functions for virtual screening. J. Med. Chem. 2001, 44, 1035-1042.
12. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 1995, 245, 43-53.
13. Kramer, B.; Rarey, M.; Lengauer, T. Evaluation of the FlexX incremental construction algorithm for protein ligand docking. Proteins: Struct. Funct., Genet. 1999, 37, 228-241.
14. Doman, T. N.; McGovern, S. L.; Witherbee, B. J.; Kasten, T. P.; Kurumbail, R.; et al. Molecular docking and high throughput screening for novel inhibitors of protein tyrosine phosphatase 1B. J. Med. Chem. 2002, 45, 2213-2221.
15. Gruneberg, S.; Stubbs, M. T.; Klebe, G. Successful virtual screening for novel inhibitors of human carbonic anhydrase: Strategy and experimental confirmation. J. Med. Chem. 2002, 45, 3588-3602.
16. Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufmann, S. H.; Prendergast, F. G.; et al. Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. J. Med. Chem. 2000, 43, 401-408.
17. Filikov, A. V.; Mohan, V.; Vickers, T. A.; Griffey, R. H.; Cook, P. D.; et al. Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR. J. Comput.-Aided Mol. Des. 2000, 14, 593-610.
18. Halperin, I.; Ma, B.; Wolfson, H.; Nussinov, R. Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins: Struct., Funct., Genet, 2002, 47, 409-443.
19. Cohen, P. Protein kinases, the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1, 309-315.
20. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature 2001, 411, 335-365.
21. Hubbard, S. R. Protein tyrosine kinases: autoregulation and small molecule inhibition. Curr. Opin. Struct. Biol. 2002, 12, 735-741.
22. SMILES; Daylight Chemical Information Systems Inc.: Santa Fe, NM, Vol. 471.
23. SMARTS; Daylight Chemical Information Systems: Santa Fe, NM, Vol. 471.
24. Gasteiger, J.; Rudolph, C.; Sadowski, J. Automatic generation of 3-D atomic coordinates for organic molecules. Tetrahedron Comput. Methodol. 1990, 3, 537-547.
25. Networks, M. Corina; Gasteiger Research: Erlangen, Germany.
26. Omega; Openeye Science Software: Sante Fe, NM, Vol. 1.0.
27. Hindle, S. A.; Rarey, M.; Buning, C.; Lengauer, T. Flexible docking under pharmacophore type constraints. J. Comput.-Aided Mol. Des. 2002, 16, 129-149.
28. Traxler, P.; Furet, P. Strategies toward the design of novel and selective tyrosine kinase inhibitors. Pharmacol. Ther. 1999, 82, 195-206.
29. Toledo, L. M.; Lydon, N. B.; Elbaum, D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. 1999, 6, 775-805.
30. Charifson, P. S.; Corkery, J. J.; Murcko, M. A.; Walters, W. P. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J. Med. Chem. 1999, 42, 5100-5109.
31. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
32. Ewing, T. J. A.; Makino, S.; Skillman, A. G.; Kontz, I. D. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases. J. Comput.-Aided Mol. Des. 2001, 15, 411-428.
33. Muegge, I. A knowledge-based scoring function for protein-ligand interactions: Probing the reference state. Perspect. Drug Discovery Des. 2000, 20, 99-114.
34. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions. 1. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput.-Aided Mol. Des. 1997, 11, 425-445.
35. Pearlman, D. A.; Charifson, P. S. Are free energy calculations useful in practice? A comparison with rapid scoring functions for the p38 MAP kinase protein system. J. Med. Chem. 2001, 44, 3417-3423.
36. Hubbard, S. R.; Till, J. H. Protein tyrosine kinase structure and function. Ann. Rev. Biochem. 2000, 69, 373-398.
37. Boehm, H.-J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; et al. Novel inhibitors of DNA Gyrase: 3-D structure based biased needle screening. Hit validation by biophysical methods, and 3-D guided optimization. A promising alternative to random screening. J. Med. Chem. 2000, 43, 2664-2674.
38. Gehlhaar, D. K.; Verkhirker, G. M.; Rejto, P. A.; Sherman, C. J.; Fogel, D. B.; Fogel, L. J.; Freer, S. T. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming Chem. Biol. 1995, 2, 317-324.
39. Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol. 2000, 295, 337-356.
40. Mitchell, J. B. O.; Laskowski, R. A.; Alex, A.; Forster, M. J.; Thornton, J. M. Bleep-potential of mean force describing protein-ligand interactions: II. Calculation of binding energies and comparison with experimental data. J. Comput. Chem. 1999, 20, 1177-1185.